menu
    • menu
    [{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Osivax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2025","type":"Series B Financing","leadProduct":"OVX836","moa":"Nucleoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Meiji Seika Pharma","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Meiji Seika Pharma \/ Meiji Seika Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Meiji Seika Pharma \/ Meiji Seika Pharma"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Cefepime","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Meiji Seika Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Meiji Seika Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Cefepime","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Meiji Seika Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Meiji Seika Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase 2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Meiji Seika Pharma \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Meiji Seika Pharma \/ Sanofi"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase 2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Meiji Seika Pharma \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Meiji Seika Pharma \/ Sanofi"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase 2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Meiji Seika Pharma \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Meiji Seika Pharma \/ Sanofi"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase 2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Meiji Seika Pharma \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Meiji Seika Pharma \/ Sanofi"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Eisai","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Safinamide Methanesulfonate","moa":"Monoamine oxidase B","graph1":"Neurology","graph2":"Approved FDF","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Meiji Seika Pharma \/ Eisai","highestDevelopmentStatusID":"15","companyTruncated":"Meiji Seika Pharma \/ Eisai"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ME3183","moa":"PDE4","graph1":"Dermatology","graph2":"Phase II","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Meiji Seika Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Meiji Seika Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase 2","graph1":"Immunology","graph2":"Approved FDF","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Meiji Seika Pharma \/ Meiji Seika Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Meiji Seika Pharma \/ Meiji Seika Pharma"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ME3183","moa":"PDE4","graph1":"Dermatology","graph2":"Phase II","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Meiji Seika Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Meiji Seika Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ME3183","moa":"PDE4","graph1":"Dermatology","graph2":"Phase II","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Meiji Seika Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Meiji Seika Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Foundation for Biomedical Research and Innovation at Kobe","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Meiji Seika Pharma \/ Foundation for Biomedical Research and Innovation at Kobe","highestDevelopmentStatusID":"4","companyTruncated":"Meiji Seika Pharma \/ Foundation for Biomedical Research and Innovation at Kobe"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Dong-A ST Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"DMB-3115","moa":"IL-12 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Meiji Seika Pharma \/ Meiji Seika Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Meiji Seika Pharma \/ Meiji Seika Pharma"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Dong-A Socio Holdings","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Phase III","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Meiji Seika Pharma \/ Dong-A Socio Holdings","highestDevelopmentStatusID":"10","companyTruncated":"Meiji Seika Pharma \/ Dong-A Socio Holdings"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Intas Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Phase III","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Meiji Seika Pharma \/ Intas Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Meiji Seika Pharma \/ Intas Pharmaceuticals"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Zhejiang Hengkang Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2023","type":"Acquisition","leadProduct":"KD-370","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Meiji Seika Pharma \/ Zhejiang Hengkang Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Meiji Seika Pharma \/ Zhejiang Hengkang Pharmaceutical"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cefditoren Pivoxil","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Meiji Seika Pharma \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Meiji Seika Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"HUYA Bioscience International","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Tucidinostat","moa":"enzyme inhibitors: inhibitors of histone deacetylase","graph1":"Oncology","graph2":"Phase II","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Meiji Seika Pharma \/ Meiji Seika Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Meiji Seika Pharma \/ Meiji Seika Pharma"},{"orgOrder":0,"company":"Meiji Seika Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pediatrics","country":"JAPAN","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Human Milk Oligosaccharide","moa":"Undisclosed","graph1":"Pediatrics","graph2":"Undisclosed","graph3":"Meiji Seika Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Meiji Seika Pharma \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Meiji Seika Pharma \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Meiji Seika Pharma

    Menu

    Meiji Seika Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Meiji Seika Pharma

                            Japan arrow
                            World Drug Safety EU
                            Not Confirmed

                            Meiji Seika Pharma

                            Japan arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OVX836

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Recipient : Osivax

                            Deal Size : $10.4 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Osivax Gains Strategic Funding for Influenza Vaccine Development

                            Details : The financing aims to fund the clinical development of OVX836, Osivax’s vaccine candidate. It is being evaluated for the treatment of influenza.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            March 04, 2025

                            Lead Product(s) : OVX836

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Recipient : Osivax

                            Deal Size : $10.4 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Meiji Seika Pharma

                            Japan arrow
                            World Drug Safety EU
                            Not Confirmed

                            Meiji Seika Pharma

                            Japan arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Belumosudil

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Sponsor : Sanofi

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Meiji Seika Launches REZUROCK® Tablets in Japan for Chronic Graft-Versus-Host Disease

                            Details : Rezurock (belumosudil mesylate), a selective ROCK2 inhibitor, is indicated for the treatment of patients with Chronic Graft-Versus-Host Disease (chronic GVHD).

                            Product Name : Rezurock

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 22, 2024

                            Lead Product(s) : Belumosudil

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Sponsor : Sanofi

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Meiji Seika Pharma

                            Japan arrow
                            World Drug Safety EU
                            Not Confirmed

                            Meiji Seika Pharma

                            Japan arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Belumosudil

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Sponsor : Sanofi

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Meiji Seika Receives Approval for REZUROCK® in Japan for Chronic Graft-Versus-Host Disease

                            Details : Rezurock (belumosudil mesylate), a selective ROCK2 inhibitor, is indicated for the treatment of patients with Chronic Graft-Versus-Host Disease (chronic GVHD).

                            Product Name : Rezurock

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 26, 2024

                            Lead Product(s) : Belumosudil

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Sponsor : Sanofi

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Meiji Seika Pharma

                            Japan arrow
                            World Drug Safety EU
                            Not Confirmed

                            Meiji Seika Pharma

                            Japan arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KD-370

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Zhejiang Hengkang Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Zhejiang Hengkang Pharmaceutical Acquires Meiji Pharmaceutical (Shandong) to Enter the Field of Green Syntheti...

                            Details : Through the acquisition, Hengkang entered the field of biosynthesis, improved the commercial production capacity of products in the field of biosynthesis, enriched its product pipeline by adding KD-370, a pentavalent vaccine, approved in Japan.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            October 01, 2023

                            Lead Product(s) : KD-370

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Zhejiang Hengkang Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Meiji Seika Pharma

                            Japan arrow
                            World Drug Safety EU
                            Not Confirmed

                            Meiji Seika Pharma

                            Japan arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Belumosudil

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Sponsor : Sanofi

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            New Drug Application for ME3208 Submitted in Japan for Chronic Graft-Versus-Host Disease

                            Details : Rezurock (belumosudil mesylate), a selective ROCK2 inhibitor, is indicated for the treatment of patients with Chronic Graft-Versus-Host Disease (chronic GVHD).

                            Product Name : Rezurock

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 27, 2023

                            Lead Product(s) : Belumosudil

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Sponsor : Sanofi

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Meiji Seika Pharma

                            Japan arrow
                            World Drug Safety EU
                            Not Confirmed

                            Meiji Seika Pharma

                            Japan arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cefepime

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available T...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            June 15, 2023

                            Lead Product(s) : Cefepime

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Meiji Seika Pharma

                            Japan arrow
                            World Drug Safety EU
                            Not Confirmed

                            Meiji Seika Pharma

                            Japan arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cefepime

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            June 05, 2023

                            Lead Product(s) : Cefepime

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Meiji Seika Pharma

                            Japan arrow
                            World Drug Safety EU
                            Not Confirmed

                            Meiji Seika Pharma

                            Japan arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Belumosudil

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Sponsor : Sanofi

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ME3208 Receives Orphan Drug Designation in Japan for Chronic Graft-Versus-Host Disease

                            Details : Rezurock (belumosudil mesylate), a selective ROCK2 inhibitor, is indicated for the treatment of patients with Chronic Graft-Versus-Host Disease (chronic GVHD).

                            Product Name : Rezurock

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 24, 2023

                            Lead Product(s) : Belumosudil

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Sponsor : Sanofi

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Meiji Seika Pharma

                            Japan arrow
                            World Drug Safety EU
                            Not Confirmed

                            Meiji Seika Pharma

                            Japan arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Foundation for Biomedical Research and Innovation at Kobe

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Novel Anti-PD-1 Agonist Antibody with Immunosuppressive Effect Discovered Through Joint Research Between Mei...

                            Details : A novel anti-PD-1 agonist monoclonal antibody, which inhibits the function of PD-1 (anti-PD-1 blocking antibodies) leading in enhanced anti-tumor immunity.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 16, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Foundation for Biomedical Research and Innovation at Kobe

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Meiji Seika Pharma

                            Japan arrow
                            World Drug Safety EU
                            Not Confirmed

                            Meiji Seika Pharma

                            Japan arrow
                            World Drug Safety EU
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ME3183

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            First Patient Dosed in Phase II Study of ME3183, a Selective PDE4 Inhibitor, in Patients with Plaque Psoriasis...

                            Details : In non-clinical studies, ME3183, a selective phosphodiesterase-4 (PDE4) inhibitor, showed greater anti-inflammatory effect and its inhibitory effect on TNF-α production was approximately 30-fold greater than the existing orally-available PDE4 inhibitor ...

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 04, 2022

                            Lead Product(s) : ME3183

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth